Is Suven Life Sciences a Good Buy After Its Q1 FY27 Results?

The Suven Life Sciences share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Suven Life Sciences is a pharmaceutical and specialty chemicals company, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 11 crore, up 349.0% year on year, while the company reported a net loss of Rs 128 crore. That combination of numbers is exactly what this article breaks down, along with what it means for the Suven Life Sciences share price from here.

This piece works through the quarter's financial highlights, the business factors behind the numbers, where the Suven Life Sciences share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Suven Life Sciences Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 11 crore	Rs 2.47 crore	349.0%
EBITDA	-Rs 125 crore	-Rs 50 crore	-149.2%
Profit Before Tax	-Rs 128 crore	-Rs 52 crore	-147.7%
Net Profit / (Loss)	-Rs 128 crore	-Rs 52 crore	-147.7%

Suven Life Sciences Q1 FY27 Performance Analysis

Check Suven Life Sciences Fundamentals on Univest Screener

Revenue growth of 349.0% for the quarter came from steady demand across the company's core business, keeping the topline trend intact for the pharmaceutical and specialty chemicals sector.

The loss for the quarter came in wider year on year at -Rs 128 crore, against -Rs 52 crore a year ago. Revenue grew 349.0% in the same period, so the business is scaling, but profitability has not yet followed, which is the central issue for anyone tracking the Suven Life Sciences share price for a turnaround.

On a sequential basis, revenue moved up 33.6% sequentially from Rs 8.30 crore in the March 2026 quarter and the net loss moved down 179.8% sequentially from -Rs 46 crore in the prior quarter, giving a fuller picture of the trend behind the Suven Life Sciences share price than the year on year comparison alone.

Key Business Factors in Q1 FY27

Revenue Trend

Suven Life Sciences' revenue grew 349.0% year on year this quarter, taking the quarterly base to Rs 11 crore in a pharmaceutical and specialty chemicals business that remains sensitive to demand and pricing cycles that ultimately feed through to the Suven Life Sciences share price.

Margin Movement

EBITDA fell to -Rs 125 crore from -Rs 50 crore, with operating margin slipping to -3500.8% from -2681.8%, pointing to cost or pricing pressure that management will need to manage through the rest of FY27.

Balance Sheet Position

Suven Life Sciences carries a low debt-to-equity ratio of 0.03, giving it a conservative balance sheet heading into the rest of FY27.

Valuation Context

Suven Life Sciences does not carry a meaningful PE multiple this quarter given its current earnings, so investors should lean on revenue and book value trends instead of the price-to-earnings ratio when assessing the Suven Life Sciences share price.

Dividend Details

No interim dividend was declared alongside Suven Life Sciences' Q1 FY27 results. The stock has not paid a meaningful dividend in the trailing twelve months. Investors tracking the Suven Life Sciences share price for income should watch the company's announcements around its next annual results for any dividend decision.

Suven Life Sciences Share Price Outlook for FY27

Suven Life Sciences remains a turnaround story rather than a steady compounder for now. Revenue growth is encouraging, but the pace at which losses shrink over the coming quarters will matter more to the Suven Life Sciences share price than the topline trend alone.

A clear, sustained narrowing of losses over the next two to three quarters would be the strongest signal for the Suven Life Sciences share price, while a stall or reversal in that trend would call for more caution.

Suven Life Sciences Stock Performance

Download the Univest iOS App or Univest Android App to track Suven Life Sciences' live share price and get daily stock updates.

The Suven Life Sciences share price was trading around Rs 379 as results season played out in late August 2026, roughly 6.1% below its 52-week high of Rs 403 and well above its 52-week low of Rs 124.

The Suven Life Sciences share price has likely already absorbed some of this quarter's disappointment, but further downside is possible if the next results confirm the same trend rather than a one-off. On profitability ratios, the company reports a return on equity of -46.73% and a book value of around Rs 24 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Profitability Risk

The quarter's profit trend is the clearest risk here. Until Suven Life Sciences shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results.

Sector and Demand Risk

As a pharmaceutical and specialty chemicals business, Suven Life Sciences' results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Suven Life Sciences share price well before the next result.

Execution Risk

Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Suven Life Sciences remains loss-making in Q1 FY27, with the loss still widening year on year alongside revenue growth of 349.0%. The Suven Life Sciences share price suits investors comfortable with a turnaround story more than those looking for near-term profitability, and position sizing should reflect that risk.

Frequently Asked Questions on Suven Life Sciences Q1 FY27 Results

What were Suven Life Sciences' Q1 FY27 results?

Ans. Suven Life Sciences reported Q1 FY27 revenue of Rs 11 crore, up 349.0% year on year, with a net loss of Rs 128 crore.

Is Suven Life Sciences a good buy after its Q1 FY27 results?

Ans. Suven Life Sciences' profitability came under pressure this quarter, which makes this a stock to watch rather than an obvious buy purely on this result. Investors should form their own view based on their own risk appetite and time horizon.

What is the Suven Life Sciences share price today?

Ans. The Suven Life Sciences share price was trading around Rs 379 in late August 2026, about 6.1% below its 52-week high of Rs 403 and well above its 52-week low of Rs 124.

What is Suven Life Sciences' revenue and profit for Q1 FY27?

Ans. Suven Life Sciences reported revenue of Rs 11 crore and a net loss of Rs 128 crore for the quarter ended June 30, 2026.

Did Suven Life Sciences declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Suven Life Sciences' Q1 FY27 results. Investors should track the company's next annual results for any dividend announcement.

Why does Suven Life Sciences not have a meaningful PE ratio?

Ans. Suven Life Sciences does not carry a meaningful price-to-earnings ratio currently because of its recent earnings performance. Investors should use revenue and book value trends instead when assessing the stock.

What are the key risks for Suven Life Sciences investors right now?

Ans. The quarter's profit trend is the clearest risk here. Until Suven Life Sciences shows a sustained improvement in margins or the bottom line, the stock is likely to stay volatile around results. Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Suven Life Sciences' promoter shareholding?

Ans. Promoter shareholding data for Suven Life Sciences was not fully available for this quarter and should be checked on the company's official filings.